"Blood Screening Market by Technology (Nucleic Acid Amplification, (Real-Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%.
Browse in-depth TOC on "Blood Screening Market"
212 – Tables
44 – Figures
235 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
The demand for donated blood is rising because of advancements
in healthcare systems and the availability of and the need for sophisticated
surgical procedures, such as cardiovascular & transplant surgery, trauma
care, and therapy for cancer and blood diseases. Emerging economies such
as China, Japan, and India are providing
lucrative opportunities for the players operating in the market.
The reagents & kits segment accounted for the largest share
of the blood screening market, by product & service segment, in 2020.
The blood screening market is segmented into reagents &
kits, instruments, and software & services. The reagents & kits
accounted for the largest share of the market in 2020, mainly due to repeated
use of reagents & kits in blood screening procedures due to the rising
blood transfusion procedures, and the high consumption.
Nucleic Acid Test segment to register the highest growth rate
during the forecast period.
The blood screening market is segmented into nucleic acid test
(NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot
assays, and next-generation sequencing (NGS). In 2020, the nucleic acid test
(NAT) segment accounted for the largest share of the market. Factors such as
the increasing adoption of NAT technology due to its higher sensitivity over
other blood screening technologies and increasing number of blood donations.
The blood banks segment accounted for the largest share of the
blood screening, by end user segment, in 2020.
Based on end users, the blood screening market is segmented into
blood banks and hospitals. In 2020, the blood banks segment accounted for the
largest share of the market. The growing number of organ transplantation
surgeries is driving the growth of this segment, and the increasing demand for
donated blood.
Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042
North America is the largest
regional market for blood screening market.
The global market is segmented into five major regions—north
America, Europe, the Asia
Pacific, Latin
America,
and the Middle East & Africa. In 2020, North
America accounted
for the largest share of the market. The North American market growth can be
attributed to the increasing healthcare spending, increasing prevalence of
chronic disorders, and the highly developed healthcare system in the US
and Canada.
The major players operating in this blood screening market are
Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories,
Inc. (US), bioMérieux (France), Bio-Rad
Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman
Coulter,
Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers
(Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical
Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US),
Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura
Biotechnology Co., Ltd. (China), Immucor, Inc. (US),
Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc.
(US), and Cepheid (US).
No comments:
Post a Comment